A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

British Journal of Cancer

Volumn 110, Issue 8, 2014, Pages 1923-1929

  Glasspool, R M ^a   Brown, R ^b   Gore, M E ^c   Rustin, G J S ^d   McNeish, I A ^e   Wilson, R H ^f   Pledge, S ^g   Paul, J ^a   MacKean, M ^h   Hall, G D ⁱ   Gabra, H ^b   Halford, S E R ^j   Walker, J ^k   Appleton, K ^k   Ullah, R ^k   Kaye, S ^c  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d MOUNT VERNON CANCER CENTRE   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^g WESTON PARK HOSPITAL   (United Kingdom)

^h WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^j IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLDEOXYCYTIDINE; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; DECITABINE; DNA; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; PROTEIN MLH1; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; DRUG DERIVATIVE; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PLATINUM; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; ALLERGIC REACTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER RECURRENCE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DNA METHYLATION; DRUG BLOOD LEVEL; DRUG DOSE INTENSIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; FEASIBILITY STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVARY CANCER; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGED; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG RESISTANCE; GENETICS; OVARY TUMOR; PATHOLOGY; TUMOR RECURRENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CARBOPLATIN; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PLATINUM;

EID: 84901828394     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.116     Document Type: Article

References (23)

1. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25: 4603-4609
2. Brown R, Hirst GL, GallagherWM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45-52
3. Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, Califano JA, Sidransky D (2010) Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 70: 2870-2879
4. DaiW, Teodoridis JM, Graham J, Zeller C, Huang TH, Yan P, Vass JK, Brown R, Paul J (2008) Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands. BMC Bioinformatics 9: 337
5. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE (2010) A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116: 4043-4053
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917
7. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK,Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC (2011) Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 117: 1661-1669
8. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R (2004) The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10: 4420-4426
9. Glasspool RM, Teodoridis JM, Brown R (2006) Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 94: 1087-1092
10. Graham JS, Kaye SB, Brown R (2009) The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer 45: 1129-1136
11. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109: 52-57
12. Kwon NH, Kim JS, Lee JY, Oh MJ, Choi DC (2008) DNA methylation and the expression of IL-4 and IFN-gamma promoter genes in patients with bronchial asthma. J Clin Immunol 28: 139-146
13. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP (2012) Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 72: 2197-2205
14. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C. Collaborators I, AGO (2003) Paclitaxel plus platinum-based chemotherapy vs conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106
15. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E. AGO-OVAR, CTG N, GCG E (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699-4707
16. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R (2000) Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60: 6039-6044
17. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21: 419-423
18. Scott NW, McPherson GC, Ramsay CR, Campbell MK (2002) The method of minimization for allocation to clinical trials. a review. Control Clin Trials 23: 662-674
19. Strathdee G, MacKean MJ, Illand M, Brown R (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341
20. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65: 8961-8967
21. Wei SH, Balch C, Paik HH, KimYS, Baldwin RL, Liyanarachchi S, Li L, Wang Z, Wan JC, Davuluri RV, Karlan BY, Gifford G, Brown R, Kim S, Huang TH, Nephew KP (2006) Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12: 2788-2794
22. Zeller C, Brown R (2010) Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. Ther Adv Med Oncol 2: 319-329
23. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31: 4567-4576.